BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Selzentry / Celsentri (Maraviroc) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Selzentry / Celsentri (Maraviroc)\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06511063-967@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Selzentry / Celsentri (Maraviroc): Phase 2 readout est. (NCT0651106
 3)
DESCRIPTION:Selzentry / Celsentri (Maraviroc)\, phase 2.\nStudy: Antiviral 
 Clinical Trial for Long Covid-19\nEstimated primary completion: November 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/maraviroc#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06511063
URL:https://assetmemo.bio/drug/maraviroc#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974084-967@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Selzentry / Celsentri (Maraviroc): Phase 2/3 readout est. (NCT06974
 084)
DESCRIPTION:Selzentry / Celsentri (Maraviroc)\, phase 2/3.\nStudy: A Multi-
 Center\, Individually-Randomized\, Double-Blind\, Placebo-Controlled\, Par
 allel-Group\, Superiority Trial to Evaluate the Efficacy of the Combinatio
 n of Maraviroc and Atorvastatin for the Treatment of Subjects With Long CO
 VID\nEstimated primary completion: 1 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/maraviroc#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06974084
URL:https://assetmemo.bio/drug/maraviroc#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06805656-967@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Selzentry / Celsentri (Maraviroc): Phase 2 readout est. (NCT0680565
 6)
DESCRIPTION:Selzentry / Celsentri (Maraviroc)\, phase 2\, HIV.\nStudy: Mult
 i Interventional Approaches to Mitigate HIV Reservoirs for the Sustained H
 IV Remission Without Antiretrovirals\nEstimated primary completion: 1 Marc
 h 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/maraviroc#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0680565
 6
URL:https://assetmemo.bio/drug/maraviroc#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05470491-967@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Selzentry / Celsentri (Maraviroc): Phase 1/2 readout est. (NCT05470
 491)
DESCRIPTION:Selzentry / Celsentri (Maraviroc)\, phase 1/2\, HIV.\nStudy: Tr
 ial of Allogeneic Reduced-Intensity\, HLA-Haploidentical Allogeneic Hemato
 poietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Dis
 ease (GVHD) Prophylaxis With Cyclophosphamide\, Bortezomib and Maraviroc f
 or Hematologic Malignancies ...\nEstimated primary completion: 30 July 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/maraviroc#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05470491
URL:https://assetmemo.bio/drug/maraviroc#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07080567-967@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Selzentry / Celsentri (Maraviroc): Phase 2 readout est. (NCT0708056
 7)
DESCRIPTION:Selzentry / Celsentri (Maraviroc)\, phase 2.\nStudy: Manipulati
 ng the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Str
 oke\nEstimated primary completion: December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/maraviroc#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07080567
URL:https://assetmemo.bio/drug/maraviroc#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06853223-967@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Selzentry / Celsentri (Maraviroc): Phase 2 readout est. (NCT0685322
 3)
DESCRIPTION:Selzentry / Celsentri (Maraviroc)\, phase 2.\nStudy: This Study
  is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment 
 to Prevent Primary Graft Dysfunction\nEstimated primary completion: 1 Apri
 l 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/maraviroc#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0685322
 3
URL:https://assetmemo.bio/drug/maraviroc#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668505-967@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Selzentry / Celsentri (Maraviroc): Phase 4 readout est. (NCT0766850
 5)
DESCRIPTION:Selzentry / Celsentri (Maraviroc)\, phase 4.\nStudy: Anti-infla
 mmation Treatment for Idiopathic Inflammatory Myopathies\nEstimated primar
 y completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/maraviroc#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07668505
URL:https://assetmemo.bio/drug/maraviroc#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
